Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopeniaTadeusz Robak, Stephen Jolles, Isidro Jarque et al.|Blood Advances|2020Cited by 109
Inhibition of <scp>FcRn</scp> with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double‐blind, placebo‐controlled phase 3 studies and their open‐label extensionNichola Cooper, David J. Kuter, Sarah Cluck et al.|British Journal of Haematology|2024Cited by 13